CNS Pharmaceuticals, Inc. Financial Ratios — CNSP Stock

Profitability (USD)

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Assets (%)	- -	-1,748.47	-90.22	-79.59	-117.8	-140.06	-255.54	-285.68	-182.99
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Gross Margin (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
EBITDA Margin (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Operating Margin (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Incremental Operating Margin (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Pretax Margin (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Income to Common Margin (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Dvd Payout Ratio (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Sustainable Growth Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -

Credit (USD)

API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Total Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -
ST Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -
LT Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Debt/EBITDA	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Debt/EBITDA	- -	-0.04	1.89	1.44	0.32	0.63	0.01	0.41	0.43
Total Debt/EBIT	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Debt/EBIT	- -	-0.04	1.89	1.44	0.32	0.63	0.01	0.41	0.43
EBITDA to Interest Expense	- -	-18.88	-86.61	-2,893.23	-1,558.73	-2,170.96	-1,366.24	-924.23	-1,049.42
EBITDA-CapEx/Interest Expense	- -	-18.88	-87.06	-2,898.73	-1,559.35	-2,171.59	-1,366.52	-924.49	-1,050.61
EBIT to Interest Expense	- -	-18.88	-86.65	-2,896.63	-1,560.14	-2,172.64	-1,366.54	-924.44	-1,049.68
Interest Expense	- -	- -	- -	- -	- -	- -	- -	- -	- -
Common Equity/Total Assets	-128.91	-1,111.99	-144.99	-131.97	-404.69	-388.52	-4,090.12	-970.29	-1,162.81
Long-Term Debt/Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Long-Term Debt/Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Long-Term Debt/Total Assets (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Debt/Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Debt/Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Debt/Total Assets (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Debt to Equity	-19.27	-6.22	-95.27	-97.51	-74.91	-118.6	5.59	-99.33	-151.96
Net Debt/Capital (%)	-5.7	-0.45	38.7	39.39	11.53	15.98	0.36	6.77	6.41
EBITDA	- -	-1	-4	-9	-14	-15	-19	-15	-16
EBITDA-CapEx	- -	-1	-4	-9	-14	-15	-19	-15	-16
Operating Income (Loss)	- -	-1	-4	-9	-14	-15	-19	-15	-16

Liquidity (USD)

API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Cash Ratio	0.5	0.23	23.28	7.37	1.93	2.04	0.09	2.56	1.76
Current Ratio	0.73	0.48	25.38	8.13	2.88	2.55	0.26	3.43	1.98
Quick Ratio	0.5	0.23	23.28	7.37	1.93	2.04	0.09	2.91	1.76
CFO/Avg Current Liab	- -	-0.99	-4.6	-6.6	-6.02	-2.81	-2.56	-3.95	-4.17
Common Equity/Total Assets	-128.91	-1,111.99	-144.99	-131.97	-404.69	-388.52	-4,090.12	-970.29	-1,162.81
Long-Term Debt/Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Long-Term Debt/Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Long-Term Debt/Total Assets (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Debt/Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Debt/Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Debt/Total Assets (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
CFO/Total Liabilities	- -	-58.12	-1,142.6	-384.06	-521.87	-214.58	-230.56	-677.93	-336.78
CFO/CapEx	- -	- -	-176.61	-407.8	-2,355.31	-2,387.57	-3,624.72	-4,086.27	-759.9
Altman's Z-Score	-2.33	-20.98	7.81	-1.7	-10.08	-8.56	-97	-18.34	-21.5

Working Capital (USD)

API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Accounts Receivable Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -
Days Sales Outstanding	- -	- -	- -	- -	- -	- -	- -	- -	- -
Inventory Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -
Days Inventory Outstanding	- -	- -	- -	- -	- -	- -	- -	- -	- -
Accounts Payable Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -
Accounts Payable Turnover Days	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cash Conversion Cycle	- -	- -	- -	- -	- -	- -	- -	- -	- -
Inventory to Cash Days	- -	- -	- -	- -	- -	- -	- -	- -	- -
Inventories	- -	- -	- -	- -	- -	- -	- -	- -	- -
Raw Materials	- -	- -	- -	- -	- -	- -	- -	- -	- -
Work In Process	- -	- -	- -	- -	- -	- -	- -	- -	- -
Finished Goods	- -	- -	- -	- -	- -	- -	- -	- -	- -
Other Inventory	- -	- -	- -	- -	- -	- -	- -	- -	- -

Enterprise Value (USD)

API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Market Capitalization	- -	- -	5	3	2	- -	1	- -	2
- Cash & Cash Equivalents	- -	- -	7	14	5	10	1	6	7
+ Preferred Equity and Hybrid Capital	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Minority/Non Controlling Interest	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Total Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -
Enterprise Value	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Capital	- -	-7	-11	-20	-35	-50	-69	-84	-100
Total Debt/Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Debt / EV	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Sales	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBITDA	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBIT	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Free Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -
Diluted Market Cap	- -	- -	5	3	2	- -	1	- -	2
Diluted Enterprise Value	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -
TTM Sales	- -	- -	- -	- -	- -	- -	- -	- -	- -
TTM EBITDA	- -	-1	-4	-9	-14	-15	-19	-15	-16
TTM Operating Income	- -	-1	-4	-9	-14	-15	-19	-15	-16
TTM Cash Flow to Firm	- -	-1	-4	-7	-14	-11	-14	-17	-14
TTM Free Cash Flow to Firm	- -	-1	-3	-7	-14	-11	-14	-17	-14

Multiples (USD)

API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Price/Free Cash Flow	- -	- -	-1.51	-0.48	-0.12	-0.03	-0.05	-0.01	-0.17
EV/EBIT	- -	- -	- -	- -	- -	- -	- -	- -	- -
Enterprise Value	- -	- -	- -	- -	- -	- -	- -	- -	- -
Low Price	- -	- -	273,757.5	94,365	51,930	5,125	1,526.25	4.78	0.73
EV/Sales	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBITDA	- -	- -	- -	- -	- -	- -	- -	- -	- -
Price/Earnings	- -	- -	- -	- -	- -	- -	- -	- -	- -
Price/Earnings Average	- -	- -	-1.41	-0.53	-0.29	-0.08	-0.05	-0.88	-0.13
Price/Earnings High	- -	- -	-1.98	-1.16	-0.72	-0.36	-0.12	-6.96	-0.3
Price/Earnings Low	- -	- -	-1.27	-0.26	-0.11	-0.02	-0.02	-0.01	-0.02
Price/Book Value	- -	- -	-0.46	-0.17	-0.05	-0.01	-0.01	- -	-0.02
Price/Book Value Average	- -	- -	-0.48	-0.24	-0.12	-0.02	-0.01	-0.16	-0.02
Price/Book Value High	- -	- -	-0.67	-0.52	-0.29	-0.11	-0.03	-1.23	-0.05
Price/Book Value Low	- -	- -	-0.43	-0.12	-0.05	-0.01	- -	- -	- -
Price/Tangible Book Value	- -	- -	0.7	0.25	0.26	0.04	-0.15	0.03	0.51
Price/Tangible Book Value Average	- -	- -	0.72	0.36	0.69	0.14	-0.21	2.12	0.46
Price/Tangible Book Value High	- -	- -	1.01	0.79	1.68	0.67	-0.51	16.74	1.04
Price/Tangible Book Value Low	- -	- -	0.65	0.18	0.26	0.03	-0.07	0.02	0.07
Price/Sales	- -	- -	- -	- -	- -	- -	- -	- -	- -
Price/Sales Average	- -	- -	- -	- -	- -	- -	- -	- -	- -
Price/Sales High	- -	- -	- -	- -	- -	- -	- -	- -	- -
Price/Sales Low	- -	- -	- -	- -	- -	- -	- -	- -	- -
Price/Cash Flow	- -	- -	-1.5	-0.47	-0.12	-0.03	-0.05	-0.01	-0.17
Price/Cash Flow Average	- -	- -	-1.54	-0.69	-0.31	-0.11	-0.07	-0.76	-0.15
Price/Cash Flow High	- -	- -	-2.16	-1.5	-0.77	-0.52	-0.16	-6.04	-0.34
Price/Cash Flow Low	- -	- -	-1.39	-0.34	-0.12	-0.03	-0.02	-0.01	-0.02
Price/Free Cash Flow Average	- -	- -	-1.55	-0.69	-0.31	-0.11	-0.07	-0.77	-0.15
Price/Free Cash Flow High	- -	- -	-2.17	-1.5	-0.77	-0.52	-0.16	-6.05	-0.34
Price/Free Cash Flow Low	- -	- -	-1.39	-0.34	-0.12	-0.03	-0.02	-0.01	-0.02
EV/Sales Average	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Sales High	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Sales Low	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBITDA Average	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBITDA High	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBITDA Low	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBIT Average	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBIT High	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBIT Low	- -	- -	- -	- -	- -	- -	- -	- -	- -
Last Price	- -	- -	296,250	133,500	52,680	6,000	3,175	6.02	5.25
High Price	- -	- -	426,742.5	421,500	334,500	103,500	11,000	3,250	10.59
Enterprise Value Average	- -	- -	- -	- -	- -	- -	- -	- -	- -
Enterprise Value High	- -	- -	- -	- -	- -	- -	- -	- -	- -
Enterprise Value Low	- -	- -	- -	- -	- -	- -	- -	- -	- -

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Shares Outstanding	- -	- -	- -	- -	- -	- -	- -	- -	1
Diluted Weighted Avg Shares	- -	- -	- -	- -	- -	- -	- -	- -	- -
Basic Weighted Avg Shares	- -	- -	- -	- -	- -	- -	- -	- -	- -
Revenue per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -
EBITDA per Share	- -	-51,869.82	-212,834.56	-363,211.96	-466,865.97	-287,836.81	-91,115.82	-468.17	-36.05
Operating Income per Share	- -	-51,869.82	-212,943.17	-363,638.73	-467,287.58	-288,058.62	-91,135.79	-468.28	-36.06
Basic EPS, GAAP	- -	-434,817.59	-215,400.61	-363,764.27	-467,587.1	-288,191.21	-91,068.72	-466.89	-35.75
Basic EPS from Cont Ops	- -	-434,817.59	-215,400.61	-363,764.27	-467,587.1	-288,191.21	-91,068.72	-466.89	-35.75
Diluted EPS, GAAP	- -	-434,817.59	-215,400.61	-363,764.27	-467,587.1	-288,191.21	-91,068.72	-466.89	-35.75
Diluted EPS from Cont Ops	- -	-434,817.59	-215,400.61	-363,764.27	-467,587.1	-288,191.21	-91,068.72	-466.89	-35.75
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cash Flow per Share	- -	-42,140.29	-197,415.11	-281,462.23	-436,719.65	-199,204.06	-68,309.33	-537.77	-31.15
Free Cash Flow per Basic Share	- -	-42,140.29	-198,532.89	-282,152.42	-436,905.06	-199,287.49	-68,328.17	-537.9	-31.19
Cash & Equivalents per Share	- -	16,631.53	402,293.78	539,980.5	161,436.03	189,724.66	2,650.83	203.04	16.24
Book Value per Share	- -	-446,974.47	-637,334.56	-804,711.04	-1,143,244.97	-956,869.06	-336,071.99	-2,652.94	-226.17
Tangible Book Value per Share	- -	-32,311.65	422,282	536,460.92	198,812.81	153,450.11	-21,411.18	194.09	10.2

CNS Pharmaceuticals, Inc.

Profitability (USD)

Credit (USD)

Liquidity (USD)

Working Capital (USD)

Enterprise Value (USD)

Multiples (USD)

Per Share Data Items (USD)